Mohammed Asmal

Mohammed Asmal, MD, PhD, is Senior Vice President, Head of Clinical at Prime Medicine. He is a physician-scientist with an AB in biology and biomedical engineering from Harvard University, and an MD-PhD in molecular and cellular biology from Columbia University. He trained in internal medicine and infectious diseases at the Brigham and Women’s and Massachusetts General Hospitals, and has devoted much of his academic career to studying the virology and immunology of HIV, and to treating patients with HIV and other infectious diseases in the clinic. After leaving academic medicine, Dr. Asmal took on roles in clinical development at Vertex Pharmaceuticals, where he led trials in oncology and hepatitis C, bringing multiple small molecules into the clinic through phase II. He subsequently transitioned to bluebird bio, where he led the clinical development team, overseeing lentiviral-based gene therapy programs in rare disease and oncology, culminating in the first approval of a gene therapy for a hemoglobinopathy in the world. Immediately prior to joining Prime Medicine, Dr. Asmal was a venture partner at OrbiMed Advisors, LLC, where he performed diligence on potential investments in the cell and gene therapy, COVID-19 and oncology spaces, and oversaw a seed stage investment in cell therapy.

Dr. Asmal has over 30 peer-reviewed scientific publications in immunology, HIV virology and in clinical trials of gene therapy for hemoglobinopathies.